Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 166

1.

Members of the public in the USA, UK, Canada and Australia expressing genetic exceptionalism say they are more willing to donate genomic data.

Middleton A, Milne R, Howard H, Niemiec E, Robarts L, Critchley C, Nicol D, Prainsack B, Atutornu J, Vears DF, Smith J, Steed C, Bevan P, Scott ER, Bobe J, Goodhand P, Kleiderman E, Thorogood A, Morley KI; Participant Values Work Stream of the Global Alliance for Genomics and Health.

Eur J Hum Genet. 2019 Nov 29. doi: 10.1038/s41431-019-0550-y. [Epub ahead of print]

PMID:
31784701
2.

Trust in genomic data sharing among members of the general public in the UK, USA, Canada and Australia.

Milne R, Morley KI, Howard H, Niemiec E, Nicol D, Critchley C, Prainsack B, Vears D, Smith J, Steed C, Bevan P, Atutornu J, Farley L, Goodhand P, Thorogood A, Kleiderman E, Middleton A; Participant Values Work Stream of the Global Alliance for Genomics and Health.

Hum Genet. 2019 Dec;138(11-12):1237-1246. doi: 10.1007/s00439-019-02062-0. Epub 2019 Sep 17.

3.

The Lived Experience of Child Marriage in the United States.

Wahi A, Zaleski KL, Lampe J, Bevan P, Koski A.

Soc Work Public Health. 2019;34(3):201-213. doi: 10.1080/19371918.2019.1575312. Epub 2019 Feb 12.

PMID:
30747055
4.

Attitudes of publics who are unwilling to donate DNA data for research.

Middleton A, Milne R, Thorogood A, Kleiderman E, Niemiec E, Prainsack B, Farley L, Bevan P, Steed C, Smith J, Vears D, Atutornu J, Howard HC, Morley KI.

Eur J Med Genet. 2019 May;62(5):316-323. doi: 10.1016/j.ejmg.2018.11.014. Epub 2018 Nov 23.

5.

A Posterior Approach to Open Reduction and Internal Fixation of Displaced Posterior Cruciate Ligament Tibial Osseous Avulsions.

Hooper PO 3rd, Bevan PJ, Silko C, Farrow LD.

JBJS Essent Surg Tech. 2018 Feb 28;8(1):e6. doi: 10.2106/JBJS.ST.17.00044. eCollection 2018 Mar 28.

6.

Regulation between personality traits: individual social tendencies modulate whether boldness and leadership are correlated.

Bevan PA, Gosetto I, Jenkins ER, Barnes I, Ioannou CC.

Proc Biol Sci. 2018 Jun 13;285(1880). pii: 20180829. doi: 10.1098/rspb.2018.0829.

7.

'Your DNA, Your Say': global survey gathering attitudes toward genomics: design, delivery and methods.

Middleton A, Niemiec E, Prainsack B, Bobe J, Farley L, Steed C, Smith J, Bevan P, Bonhomme N, Kleiderman E, Thorogood A, Schickhardt C, Garattini C, Vears D, Littler K, Banner N, Scott E, Kovalevskaya NV, Levin E, Morley KI, Howard HC.

Per Med. 2018 Jul 1;15(4):311-318. doi: 10.2217/pme-2018-0032. Epub 2018 Jun 1.

8.

Incidence of spinal epidural lipomatosis in patients with spinal stenosis.

Malone JB, Bevan PJ, Lewis TJ, Nelson AD, Blaty DE, Kahan ME.

J Orthop. 2017 Nov 6;15(1):36-39. doi: 10.1016/j.jor.2017.11.001. eCollection 2018 Mar.

9.

Enhanced anti-tumour activity of the combination of the novel MEK inhibitor WX-554 and the novel PI3K inhibitor WX-037.

Haagensen EJ, Thomas HD, Schmalix WA, Payne AC, Kevorkian L, Allen RA, Bevan P, Maxwell RJ, Newell DR.

Cancer Chemother Pharmacol. 2016 Dec;78(6):1269-1281. doi: 10.1007/s00280-016-3186-4. Epub 2016 Nov 11.

10.

Adjuvant Weekly Girentuximab Following Nephrectomy for High-Risk Renal Cell Carcinoma: The ARISER Randomized Clinical Trial.

Chamie K, Donin NM, Klöpfer P, Bevan P, Fall B, Wilhelm O, Störkel S, Said J, Gambla M, Hawkins RE, Jankilevich G, Kapoor A, Kopyltsov E, Staehler M, Taari K, Wainstein AJA, Pantuck AJ, Belldegrun AS.

JAMA Oncol. 2017 Jul 1;3(7):913-920. doi: 10.1001/jamaoncol.2016.4419.

11.

A phase I pharmacokinetic and pharmacodynamic study of the oral mitogen-activated protein kinase kinase (MEK) inhibitor, WX-554, in patients with advanced solid tumours.

Jamieson D, Griffin MJ, Sludden J, Drew Y, Cresti N, Swales K, Merriman M, Allen R, Bevan P, Buerkle M, Mala C, Coyle V, Rodgers L, Dean E, Greystoke A, Banerji U, Wilson RH, Evans TR, Anthoney A, Ranson M, Boddy AV, Plummer R.

Eur J Cancer. 2016 Nov;68:1-10. doi: 10.1016/j.ejca.2016.08.026. Epub 2016 Sep 28.

PMID:
27693888
12.

Body Mass Index and Survival in a Prospective Randomized Trial of Localized High-Risk Renal Cell Carcinoma.

Donin NM, Pantuck A, Klöpfer P, Bevan P, Fall B, Said J, Belldegrun AS, Chamie K.

Cancer Epidemiol Biomarkers Prev. 2016 Sep;25(9):1326-32. doi: 10.1158/1055-9965.EPI-16-0226. Epub 2016 Jul 14.

13.

Trust and British Gas partner in EPC scheme.

Bevan P.

Health Estate. 2015 Feb;69(2):42-6.

PMID:
26268017
14.

Carbonic anhydrase-IX score is a novel biomarker that predicts recurrence and survival for high-risk, nonmetastatic renal cell carcinoma: Data from the phase III ARISER clinical trial.

Chamie K, Klöpfer P, Bevan P, Störkel S, Said J, Fall B, Belldegrun AS, Pantuck AJ.

Urol Oncol. 2015 May;33(5):204.e25-33. doi: 10.1016/j.urolonc.2015.02.013. Epub 2015 Mar 29.

PMID:
25823535
15.

Should Cerebral Near-infrared Spectroscopy be Standard of Care in Adult Cardiac Surgery?

Bevan PJ.

Heart Lung Circ. 2015 Jun;24(6):544-50. doi: 10.1016/j.hlc.2015.01.011. Epub 2015 Feb 7. Review.

PMID:
25735719
16.

Monoclonal antibody G250 targeting CA Ⅸ: Binding specificity, internalization and therapeutic effects in a non-renal cancer model.

Zatovicova M, Jelenska L, Hulikova A, Ditte P, Ditte Z, Csaderova L, Svastova E, Schmalix W, Boettger V, Bevan P, Pastorek J, Pastorekova S.

Int J Oncol. 2014 Dec;45(6):2455-67. doi: 10.3892/ijo.2014.2658. Epub 2014 Sep 17.

PMID:
25230982
17.

Long-term survival after isolated tricuspid valve replacement.

Bevan PJ, Haydock DA, Kang N.

Heart Lung Circ. 2014 Aug;23(8):697-702. doi: 10.1016/j.hlc.2014.02.011. Epub 2014 Mar 6.

PMID:
24680484
18.

Accounting for the impact of conservation on human well-being.

Milner-Gulland EJ, McGregor JA, Agarwala M, Atkinson G, Bevan P, Clements T, Daw T, Homewood K, Kumpel N, Lewis J, Mourato S, Palmer Fry B, Redshaw M, Rowcliffe JM, Suon S, Wallace G, Washington H, Wilkie D.

Conserv Biol. 2014 Oct;28(5):1160-6. doi: 10.1111/cobi.12277. Epub 2014 Mar 18.

19.

Spontaneous chest wall hematoma with dual antiplatelet therapy.

Bevan P, Menon A, Bunton R.

Can J Cardiol. 2014 Feb;30(2):247.e1-2. doi: 10.1016/j.cjca.2013.08.021. Epub 2013 Nov 28.

PMID:
24290862
20.
21.

Positron emission tomography/computed tomography identification of clear cell renal cell carcinoma: results from the REDECT trial.

Divgi CR, Uzzo RG, Gatsonis C, Bartz R, Treutner S, Yu JQ, Chen D, Carrasquillo JA, Larson S, Bevan P, Russo P.

J Clin Oncol. 2013 Jan 10;31(2):187-94. doi: 10.1200/JCO.2011.41.2445. Epub 2012 Dec 3. Erratum in: J Clin Oncol. 2018 Jan 1;36(1):98.

22.

Interpretation of genomic copy number variants using DECIPHER.

Corpas M, Bragin E, Clayton S, Bevan P, Firth HV.

Curr Protoc Hum Genet. 2012 Jan;Chapter 8:Unit 8.14. doi: 10.1002/0471142905.hg0814s72.

PMID:
22241657
23.

Development of a platform for co-registered ultrasound and MR contrast imaging in vivo.

Chandrana C, Bevan P, Hudson J, Pang I, Burns P, Plewes D, Chopra R.

Phys Med Biol. 2011 Feb 7;56(3):861-77. doi: 10.1088/0031-9155/56/3/020. Epub 2011 Jan 17.

PMID:
21242630
24.

Microbubble mediated sonoporation of cells in suspension: clonogenic viability and influence of molecular size on uptake.

Karshafian R, Samac S, Bevan PD, Burns PN.

Ultrasonics. 2010 Jun;50(7):691-7. doi: 10.1016/j.ultras.2010.01.009. Epub 2010 Jan 25.

PMID:
20153497
25.

Resilience and response to hazards and threats, everybody's business.

Bevan P.

Trans Med Soc Lond. 2010-2011;127:5-12. No abstract available.

PMID:
24941633
26.

Sonoporation by ultrasound-activated microbubble contrast agents: effect of acoustic exposure parameters on cell membrane permeability and cell viability.

Karshafian R, Bevan PD, Williams R, Samac S, Burns PN.

Ultrasound Med Biol. 2009 May;35(5):847-60. doi: 10.1016/j.ultrasmedbio.2008.10.013. Epub 2008 Dec 24.

PMID:
19110370
27.

Carbonic anhydrase IX: role in diagnosis prognosis and cancer therapy. Introduction.

Belldegrun AS, Bevan P.

BJU Int. 2008 Jun;101 Suppl 4:1. doi: 10.1111/j.1464-410X.2008.07640.x. No abstract available.

28.

The influence of fragmentation on the acoustic response from shrinking bubbles.

Bevan PD, Karshafian R, Burns PN.

Ultrasound Med Biol. 2008 Jul;34(7):1152-62. doi: 10.1016/j.ultrasmedbio.2007.12.016. Epub 2008 Mar 14.

PMID:
18343022
29.

In vitro characterization of the subharmonic ultrasound signal from Definity microbubbles at high frequencies.

Cheung K, Couture O, Bevan PD, Cherin E, Williams R, Burns PN, Foster FS.

Phys Med Biol. 2008 Mar 7;53(5):1209-23. doi: 10.1088/0031-9155/53/5/004. Epub 2008 Feb 11.

PMID:
18296758
30.

The Role of uPA and uPA Inhibitors in Breast Cancer.

Bevan P, Mala C.

Breast Care (Basel). 2008;3(s2):1-2. Epub 2008 Oct 15. No abstract available.

31.

Quantitative measurement of ultrasound disruption of polymer-shelled microbubbles.

Bevan PD, Karshafian R, Tickner EG, Burns PN.

Ultrasound Med Biol. 2007 Nov;33(11):1777-86. Epub 2007 Jul 25.

PMID:
17656011
32.

A model for reflectivity enhancement due to surface bound submicrometer particles.

Couture O, Bevan PD, Cherin E, Cheung K, Burns PN, Foster FS.

Ultrasound Med Biol. 2006 Aug;32(8):1247-55.

PMID:
16875958
33.
34.

Investigating perfluorohexane particles with high-frequency ultrasound.

Couture O, Bevan PD, Cherin E, Cheung K, Burns PN, Foster FS.

Ultrasound Med Biol. 2006 Jan;32(1):73-82. Erratum in: Ultrasound Med Biol. 2006 Jul;32(7):1129.

PMID:
16364799
35.

An overview of Ensembl.

Birney E, Andrews TD, Bevan P, Caccamo M, Chen Y, Clarke L, Coates G, Cuff J, Curwen V, Cutts T, Down T, Eyras E, Fernandez-Suarez XM, Gane P, Gibbins B, Gilbert J, Hammond M, Hotz HR, Iyer V, Jekosch K, Kahari A, Kasprzyk A, Keefe D, Keenan S, Lehvaslaiho H, McVicker G, Melsopp C, Meidl P, Mongin E, Pettett R, Potter S, Proctor G, Rae M, Searle S, Slater G, Smedley D, Smith J, Spooner W, Stabenau A, Stalker J, Storey R, Ureta-Vidal A, Woodwark KC, Cameron G, Durbin R, Cox A, Hubbard T, Clamp M.

Genome Res. 2004 May;14(5):925-8. Epub 2004 Apr 12. Review.

36.

Ensembl 2004.

Birney E, Andrews D, Bevan P, Caccamo M, Cameron G, Chen Y, Clarke L, Coates G, Cox T, Cuff J, Curwen V, Cutts T, Down T, Durbin R, Eyras E, Fernandez-Suarez XM, Gane P, Gibbins B, Gilbert J, Hammond M, Hotz H, Iyer V, Kahari A, Jekosch K, Kasprzyk A, Keefe D, Keenan S, Lehvaslaiho H, McVicker G, Melsopp C, Meidl P, Mongin E, Pettett R, Potter S, Proctor G, Rae M, Searle S, Slater G, Smedley D, Smith J, Spooner W, Stabenau A, Stalker J, Storey R, Ureta-Vidal A, Woodwark C, Clamp M, Hubbard T.

Nucleic Acids Res. 2004 Jan 1;32(Database issue):D468-70.

37.

Ensembl 2002: accommodating comparative genomics.

Clamp M, Andrews D, Barker D, Bevan P, Cameron G, Chen Y, Clark L, Cox T, Cuff J, Curwen V, Down T, Durbin R, Eyras E, Gilbert J, Hammond M, Hubbard T, Kasprzyk A, Keefe D, Lehvaslaiho H, Iyer V, Melsopp C, Mongin E, Pettett R, Potter S, Rust A, Schmidt E, Searle S, Slater G, Smith J, Spooner W, Stabenau A, Stalker J, Stupka E, Ureta-Vidal A, Vastrik I, Birney E.

Nucleic Acids Res. 2003 Jan 1;31(1):38-42.

38.

B-scan ultrasound imaging of thermal coagulation in bovine liver: frequency shift attenuation mapping.

Bevan PD, Sherar MD.

Ultrasound Med Biol. 2001 Jun;27(6):809-17.

PMID:
11516541
39.
40.

Insulin signalling.

Bevan P.

J Cell Sci. 2001 Apr;114(Pt 8):1429-30. Review. No abstract available.

41.
42.

In vivo efficacy of XR9051, a potent modulator of P-glycoprotein mediated multidrug resistance.

Mistry P, Plumb J, Eccles S, Watson S, Dale I, Ryder H, Box G, Charlton P, Templeton D, Bevan PB.

Br J Cancer. 1999 Apr;79(11-12):1672-8.

43.

Reversal of P-glycoprotein-mediated multidrug resistance by XR9051, a novel diketopiperazine derivative.

Dale IL, Tuffley W, Callaghan R, Holmes JA, Martin K, Luscombe M, Mistry P, Ryder H, Stewart AJ, Charlton P, Twentyman PR, Bevan P.

Br J Cancer. 1998 Oct;78(7):885-92.

44.

Novel low-molecular-weight inhibitor of PAI-1 (XR5118) promotes endogenous fibrinolysis and reduces postthrombolysis thrombus growth in rabbits.

Friederich PW, Levi M, Biemond BJ, Charlton P, Templeton D, van Zonneveld AJ, Bevan P, Pannekoek H, ten Cate JW.

Circulation. 1997 Aug 5;96(3):916-21.

PMID:
9264501
45.

Regulation of neuronal and recombinant GABA(A) receptor ion channels by xenovulene A, a natural product isolated from Acremonium strictum.

Thomas P, Sundaram H, Krishek BJ, Chazot P, Xie X, Bevan P, Brocchini SJ, Latham CJ, Charlton P, Moore M, Lewis SJ, Thornton DM, Stephenson FA, Smart TG.

J Pharmacol Exp Ther. 1997 Aug;282(2):513-20.

PMID:
9262310
46.

The first anastomosis workshop, March 1981.

Bevan PG.

Ann R Coll Surg Engl. 1997 Jul;79(4 Suppl):168-9. No abstract available.

PMID:
9496167
47.

Schubert and syphilis.

Bevan PG, Rold RL.

J Med Biogr. 1996 Aug;4(3):184-5. No abstract available.

PMID:
11616310
48.

Evaluation of a low molecular weight modulator of human plasminogen activator inhibitor-1 activity.

Charlton PA, Faint RW, Bent F, Bryans J, Chicarelli-Robinson I, Mackie I, Machin S, Bevan P.

Thromb Haemost. 1996 May;75(5):808-15.

PMID:
8725728
49.

Identifying small-molecule lead compounds: the screening approach to drug discovery.

Bevan P, Ryder H, Shaw I.

Trends Biotechnol. 1995 Mar;13(3):115-21.

PMID:
7766218
50.

B-cell non-Hodgkin's lymphoma cell line (Karpas 1106) with complex translocation involving 18q21.3 but lacking BCL2 rearrangement and expression.

Nacheva E, Dyer MJ, Metivier C, Jadayel D, Stranks G, Morilla R, Heward JM, Holloway T, O'Connor S, Bevan PC, et al.

Blood. 1994 Nov 15;84(10):3422-8.

PMID:
7949096

Supplemental Content

Support Center